Rhumbline Advisers Aligos Therapeutics, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.04 - $2.14 $17,718 - $36,459	-17,037 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.08 - $12.2 $8,087 - $47,433	3,888 Added 29.57%	17,037 $37,000
Q4 2021 Feb 10, 2022	SELL	$11.48 - $17.69 $5,166 - $7,960	-450 Reduced 3.31%	13,149 $156,000
Q3 2021 Nov 12, 2021	BUY	$14.57 - $17.72 $15,429 - $18,765	1,059 Added 8.44%	13,599 $211,000
Q2 2021 Aug 05, 2021	BUY	$20.3 - $33.6 $254,562 - $421,344	12,540 New	12,540 $256,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.